AzTrials
AzTrials

InfertilityPhase 1NCT02493933

Phytoestrogen, NO Donors, N-acetyl Cysteine Add Therapy to Clomiphene Citrate to Improve Pregnancy Rate in PCO Patients

A Phase 1 study testing Phytoestrogens, Isosorbid mononitrate, N-acetyl cysteine in people with Infertility, run by Kasr El Aini Hospital.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

To evaluate the effect of oral Phytoestrogen or Isosorbid mononitrate or N-acetyl cysteine as an adjuvant to clomiphene citrate on induction of ovulation and pregnancy outcomes in patients with PCOS. In this three-arm open RCT, 240 PCOS infertile women were randomly divided to 3 groups for induction of ovulation. Read more about this study

Who is it for?
Ages 20 to 40 years, women only
Conditions the study is for
Infertility
What is being tested?
Phytoestrogens, Isosorbid mononitrate, N-acetyl cysteine
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
240 participants
Where
No sites listed yet
Study dates
Jul 2015to Dec 2015
Phase
Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 to 40 years
  • Women only
  • No healthy volunteers
  • Adult

Who may be able to join

  • All patients have PCOS.
  • All patients received CC 100 mg/day for 5 days starting from day 5 with successful ovulation as documented by folliculometry and midluteal serum progesterone with no pregnancy achieved.
  • All patients have patent fallopian tubes by Hysterosalpingography.
  • Their husbands have normal semen analysis according to the modified criteria of WHO.
  • All patients have normal serum prolactin and thyroid profile.
  • Any patient having vaginitis was treated before starting induction.

Who cannot join

  • Other causes of infertility than anovulation.
  • Diabetes or other endocrinological disorders.
  • Age > 40 years.
  • Smoking.
  • Alcohol use.
  • Presence of ovarian cyst >2cm on the second day of the cycle.
Show all 9Show fewer
  • Patients who have received gonadotrophins in the preceeding 6 months.
  • Patients who have done unilateral or bilateral ovarian drilling.
  • Allergy to PE, NO donors or NAC

About this study

Official title: Phytoestrogen, NO Donors, N-acetyl Cysteine Add Therapy to Clomiphene

To evaluate the effect of oral Phytoestrogen or Isosorbid mononitrate or N-acetyl cysteine as an adjuvant to clomiphene citrate on induction of ovulation and pregnancy outcomes in patients with PCOS. In this three-arm open RCT, 240 PCOS infertile women were randomly divided to 3 groups for induction of ovulation. Group A, [PE group, n= 80] patients received CC 100mg/d plus oral Phytoestrogen120 mg/ day and patients in Group B, [ISMN group, n=80] received CC 100 mg/d plus 20 mg Isosorbid mononitrate and Group C, [NAC group, n=80] patients received CC 100 mg/d plus NAC 1200 mg/day.

Conditions
Infertility
Being tested
Phytoestrogens, Isosorbid mononitrate, N-acetyl cysteine
Medical subject headings
Infertility

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Phytoestrogens, Isosorbid mononitrate, N-acetyl cysteineDrug

Study groups in NCT02493933
Study groupRoleWhat they receive
PhytoestrogenActive comparatorPatients received oral PE 120 mg/ day in the form of dry coated tablets (Klimadynon, Bionorica, Germany) 2 tablets three times daily from day 1 to day 12 as adjuvant to CC in the follicular phase of the cycle.
Receives: Drug: Phytoestrogens, Isosorbid mononitrate, N-acetyl cysteine
Isosorbid mononitrateActive comparatorPatients received in addition to CC 20 mg Isosorbid mononitrate (ISMN) tablet (EFFOX, Minapharm Co., Egypt under licence of Shwartz pharma,Germany) applied vaginally from day 1 to day 12 of the cycle.
Receives: Drug: Phytoestrogens, Isosorbid mononitrate, N-acetyl cysteine
N-Acetyl cysteineActive comparatorPatients received supplementation to CC with NAC 1200 mg/day orally (N-acetyl cysteine, Sedico, Cairo, ARE) sachets 200 mg each, as two sachets thrice daily from day 1 to day 12 of the cycle.
Receives: Drug: Phytoestrogens, Isosorbid mononitrate, N-acetyl cysteine

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. clinical pregnancy rate

    Measured: 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 Jul 2015 (estimated)
  2. Study startJul 2015
  3. Primary completionDec 2015 (estimated)
  4. Study completionDec 2015 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
240 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02493933
Sponsor's protocol ID
43-2015
Status last verified
Jul 2015
First submitted
7 Jul 2015
Last updated
14 Jul 2015
Results posted
No

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing Phytoestrogens, Isosorbid mononitrate, N-acetyl cysteine in people with Infertility, run by Kasr El Aini Hospital.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 14 Jul 2015. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

clinical pregnancy rate (time frame: 6 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Jul 2015.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in